

## handbook of CLINICAL DRUG DATA

FIFTH EDITION

Editors

Philip O. Anderson, Pharm.D.

Assistant Editor

Larry Jay Davis, Pharm.D.

Contributing Editors

William D. Ball, Pharm.D.

William G. Troutman, Pharm.D.

R98-62 E19-5



# handbook of CLINICAL DRUG DATA

FIFTH EDITION

15 N 0-914788 11 2 4abk

**Editors** 

copyridm nolder

James E. Knoben, Pharm.D. Philip O. Anderson, Pharm.D.

Pharmacolory - Handbooks, manuals elu-

Assistant Editor

Larry Jay Davis, Pharm.D.

William D. Ball, Pharm.D.
William G. Troutman, Pharm.D.

#### Copyright © 1983 by Drug Intelligence Publications, Inc.

all rights reserved

No part of this book may be reproduced in any form without written permission of the copyright holder

#### Library of Congress Cataloging in Publication Data

Knoben, James E.

Handbook of clinical drug data.

Includes bibliographies and index.

1. Pharmacology — Handbooks, manuals, etc. 2. Drugs — Handbooks, manuals, etc. 1. Anderson, Philip 0. II. Title. [DNLM: 1. Drugs. QV 55 H2464] RM300.K5 1983 615′.1 82-22145 ISBN 0-914768-41-7 (pbk.)

First Printing, January 1983 Second Printing, August 1983



#### PREFACE TO THE FIFTH EDITION

WITH THE INTRODUCTION OF EVER-INCREASING NUMBERS OF DRUGS and the concomitant growth in the drug literature, the need for a concise, yet comprehensive, compilation of clinically useful drug information is essential. The Handbook of Clinical Drug Data was

developed to meet this need. and product a resultant meet an action of the meet this need.

The Fourth Edition was especially well received, reflecting the utility of a new format and an expanded scope of information. Those familiar with the Fourth Edition will therefore be pleased with the even greater attention to clinically relevant data and extensive documentation (over 2300 cited references) in this edition. The addition of expert contributors, each of whom wrote within his or her area of clinical specialty, is largely responsible for this improved perspective.

Other major improvements are the inclusion of new areas achieving recent clinical advancements, such as nutritional assessment, parenteral nutrition and cancer chemotherapy. The drug monograph format has also been enhanced by the addition of new headings dealing with pharmacologic action and individualization of drug dosage. New topics have been added to both the Drug-Induced Diseases and Medical Emergencies chapters. All other chapters in the book have been completely

revised and updated.

This revision could not have been accomplished without the assistance of many people. Larry Davis, Bill Ball and Bill Troutman have been instrumental in the development of the book over the years and have helped greatly in the preparation of this edition. The contributions of Dr. Art Watanabe to the development of previous editions of the book are also appreciated. We owe a real debt of gratitude to the many Contributors who spent countless hours researching and distilling the current literature and to Dr. Dianne Tobias who compiled the index. And to our distinguished medical and pharmacy colleagues for their invaluable review and critique of the manuscript, we are most appreciative: David N. Bailey, M.D., Steven L. Barriere, Pharm.D., Robert A. Bauernfeind. M.D., C.H. Beck, Jr., M.D., Kanu Chatterjee, M.D., Gerald F. Chernoff, Ph.D., Unamarie Clibon, Pharm.D., Martin G. Cogan, M.D., R. Dennis Collins, M.D., Robert A. Curtis, Pharm.D., Alexander M. Gilderman, Pharm.D., Mark R. Green, M.D., Leslie Hendeles, Pharm.D., Jon I. Isenberg, M.D., H. William Kelly, Pharm.D., Mary Anne Koda-Kimble, Pharm.D., James R. Lane, Pharm.D., Anthony S. Manoguerra, Pharm.D., Arnold S. Milstein, M.D., Pobert J. Michocki, Pharm.D., Katherine L. Sheehan, M.D., Carol A. Stoner, Pharm.D., John F. Thompson, Pharm.D., and Helmuth Vorherr, M.D. Finally, Mary Ann Jaske of Drug Intelligence Publications deserves special thanks for her exceptional efforts in preparing the manuscript for publication.



## PREFACE TO THE FIFTH EDITION WITH THE INTERESTING NUMBER STATE ON

THE INDICATIONS, DOSAGES, and other drug information presented in this Handbook conform to that found in the medical literature or in the manufacturer's product literature. However, this Handbook provides only the more important elements of prescribing data, and is not a comprehensive drug information source. The manufacturer's current product information or other standard references should always be consulted for more detailed information, especially before prescribing is undertaken.

The addition of expert contributors, each of whom, wrote within, his or her area or clinical specialty, is largely responsible for this traceway perspective.

Other major improvements are the inclusion of new areas achieving recent clinical advancements, such as nutritional assetsment, parenteral nutrition and cance chemothers; y. The drug monograph format has also been entanced by the addition of new broadings dealing with pharmacologic action and indidualization of drug dosage, New topics have been added to both the Drug-Induced Diseases and Medical Emergencies chapters. All other chapters in the book have been completely revised and updated.

This revision coard not have been accomplished without the asstrance of many people. Larry Bavis, Bill Bail and Bill Troutman have been instrumental in the development of the rook over the years and have helped greatly in the preparation of this cultion, the contributions of Dr. Art Watanabe to the development of previous editions of the book are also appreciated. We owe a real previous editions of the many Contributors who spent countiess hours researching and distilling the current illerature and to Dr. Dranne Tobias who compiled the index, and to our distinguished medical and pharmacy colleagues for their invaluable review and critique of are manuscript, we are nost appreciative David N. Belley, M.D. Steven L. Barriere, Pharm.D., Robert A. Bauernfeind, and f. Ph.D., Uhamavie Offloor, Pharm.D., Martin G. Occan, M.D., R. Dornis Collins, M.D., Robert A. Curtis, Pharm.D., Uhamavie Offloor, Pharm.D., Martin G. Occan, M.D., R. Chern, D., John Pharm.D., Mark R. Green, M.D., Lestie Hendeles, Anne Koarkimble, Pharm.D., Mark R. Green, M.D., Lestie Hendeles, Anne Koarkimble, Pharm.D., Mark R. Green, M.D., Lestie Hendeles, Anne Koarkimble, Pharm.D., Alames R. Lane, Pharm.D., Annony Anne Koarkimble, Pharm.D., Atheriba. L. Sheehan, M.D., Carol A. Stoner, M.D., Finally, M. Ny Yann Jaske of Drug Intelligence Publications deserves special thanks for her exceptional efforts in proparing the manasce; pt for problemen.

ASE JUNEA BAMAN A. ACRESTA O SUIHA



#### EDITORS AND CONTRIBUTORS

### Editors

#### James E. Knoben, Pharm.D., M.P.H.

Chief, Drug Information Analysis Branch
Division of Drug Information Resources
National Center for Drugs and Biologics
Food and Drug Administration
Rockville, Maryland

#### Philip O. Anderson, Pharm.D.

University of California Medical Center
Assistant Clinical Professor of Pharmacy
University of California, San Francisco,
San Diego Program
San Diego, California

#### Assistant Editor

#### Larry Jay Davis, Pharm.D.

Clinical Pharmacist, Moffitt Hospital
University of California Medical Center
Assistant Clinical Professor of Pharmacy
University of California, San Francisco
San Francisco, California

#### Contributing Editors

#### William D. Ball, Pharm.D.

Clinical Pharmacist
Department of Pharmacy Services
University Hospitals of Cleveland
Cleveland, Ohio

#### William G. Troutman, Pharm.D.

Director, New Mexico Poison, Drug
Information and Medical Crisis Center Day Red L
Associate Professor of Pharmacy Mexico Information A John Mexico Information A Albuquerque, New Mexico Information Information Information



Richard C. Andersen, Pharm.D. VA 2801103

Clinical Pharmacist, San Francisco Poison Control Center Assistant Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco San Francisco, California

Jerry L. Bauman, Pharm.D.

Clinical Pharmacist/Cardiology, Department of Pharmacy, University of Illinois Hospital Assistant Professor of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Illinois

Lawrence R. Borgsdorf, Pharm.D.

Clinical Pharmacist, Department of Medicine, Kern Medical Center Assistant Professor of Medicine, School of Medicine, IU University of California, Los Angeles, India Inspense A Kern Medical Center Program and the Original Bakersfield, California

Ronald R. Conte, Pharm.D.

Clinical Pharmacist, Outpatient Department,
San Francisco General Hospital
Associate Clinical Professor of Pharmacy, School of Pharmacy,
University of California, San Francisco
San Francisco, California

Betty Jean Dong, Pharm D. 101880 to vita svinU

Clinical Pharmacist, Family Practice, San Francisco General Hospital Associate Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco San Francisco, California

Robert T. Dorr, MSNO Editing Contribution

Chief, Cancer Research Pharmacy Service, Cancer Center Division, and Research Associate, Department of Internal Medicine, University of Arizona Taiosman Service Service Center Division, and Research Associate, Department of Internal Medicine, University of Arizona Programment Services

Robert C. Eschbach, Pharm.D.

Assistant Professor of Clinical Pharmacy, College of Pharmacy, University of New Mexico Albuquerque, New Mexico

John G. Gambertoglio, Pharm.D.s notemptal

Clinical Pharmacist, Kidney Transplant Service, and A Adjunct Associate Professor of Pharmacy, School of Pharmacy, University of California, San Francisco, California

Philip D. Hansten, Pharm.D.
Associate Professor of Clinical Pharmacy, College of Pharmacy,
Washington State University
Pullman, Washington

George M. Lasezkay, Pharm.D.

Assistant Professor, Clinical Pharmacokinetics Laboratory, Department of Pharmacy, Millard Fillmore Hospital, State University of New York at Buffalo Buffalo, New York

Tara K. Mochizuki, Pharm.D.

Clinical Pharmacist, Department of Pharmacy, University of California Medical Center Assistant Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco, San Diego Program San Diego, California

Robert E. Pachorek, Pharm.D.

Clinical Pharmacist, Department of Pharmacy, ACC ACA Mercy Hospital and Medical Center
San Diego, California

Fred Shatsky, B.S. Pharm.

Coordinator, Nutritional and Metabolic Support, Avance of University of California Medical Center
Assistant Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco, San Diego Program San Diego, California

Sam K. Shimomura, Pharm.D.

Vice Chairman, Division of Clinical Pharmacy, and Associate Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco, U.C. Irvine/Long Beach Memorial Hospital Program Irvine, California

John K. Siepler, Pharm.D. OTTEM HODAMRARG

Clinical Pharmacist, Department of Pharmacy, University of California Medical Center Davis, California

Raymond E. Smith, Pharm.D.

Clinical Pharmacist, Department of Pharmacy, University of California Medical Center Assistant Clinical Professor of Pharmacy, School of Pharmacy, University of California, San Francisco, San Diego Program San Diego, California

Glen L. Stimmel, Pharm.D.

Associate Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, Schools of Pharmacy and Medicine, University of Southern California
Los Angeles, California

Dianne E. Tobias, Pharm.D.

Consultant Pharmacist, Long Term Care Practice
Assistant Clinical Professor of Pharmacy, School of Pharmacy,
University of California, San Francisco, U.C. Irvine Program
Irvine, California

Lal J. Wong, Pharm.D.

Pharmacist Specialist, Inpatient Pharmacy, Modern Modern Kalser Foundation Hospital Modern Mo



# Control Promoctet Dead And Control Con

Tare IC Mouthfalk!, Pharm.D.

PREFACE TO THE FIFTH EDITION  Control of the contro	VII
DATA COMPILATIONS	
1 ABBREVIATIONS AND CONVERSION FACTORS J.E. Knoben Medical Record and Prescription Abbreviations	iooge iU
Conversion Factors  Milliequivalents  Temperature  Weights and Measures	99 6
PHARMACEUTICS AND PHARMACOKINETICS General Principles  G.M. Lasezkay Dosing in Renal Impairment W.D. Ball Dialysis of Drugs  R.C. Andersen,	ivil rrioL 8 Clini
3 BODY MEASUREMENTS	Riskynt Citral
Creatinine Clearance Nomogram	44 45 45
Children Chamada State A Company	
Potassium Content of Selected Foods and Salt Substitutes Recommended Daily Dietary Allowances Sodium Content of Selected Drugs Sugar-Free Liquid Pharmaceuticals	48 50
Tyramine in Food and Beverages	57

		*	CONTENTS	xi
5	DRUG-INDUCED DISCOLOR	PATION	OF	
20	FECES AND URINE	J.E. Ki		59
6	DRUG-INDUCED DISEASES	W.G. Trou	ıtman	
	Blood Dyscrasias	ไล้เป็น เวลที่	trati	62
	Hepatotoxicity	eltevA etc		74
	Nephrotoxicity			85
	Oculotoxicity			94
26	Ckin Disordore	ninogty co		105
79	AUDIOLOS — RUESON	ntifungala		
85.7	DRUG INTERACTIONS			109
8.8	DRUGS AND BREAST	P.O. And	lerson	128
9	DRUGS AND PREGNANCY	T.K. Mod	hizuki	148
10	GERIATRIC DRUG USE	D.E.	Tobias	164
11	IMMUNIZATION SINSPA STA			182
32	General Recommendations			185
12	LABORATORY INDICES	P.D. Ha	ansten	187
13	MEDICAL EMERGENCIES			
•	Anaphylaxis	L.R. Bor	gsdorf	194
	Cardiac Arrest	L.R. Bor	gsdorf	195
	Poisoning	W.G. Tro		201
	Status Epilepticus	L.R. Bor	gsdorf	204
14	NUTRITIONAL ASSESSME		hatsky	208
15	PHARMACOGENETICS	P.O. And	derson	226
16	SCHEDULES OF CONTROL			238
	etic (Adrenargic)			
	11092 108 DRUG REVI	EWS	ğΑ	
17	DRUG REVIEWS			
	Introductional Sugrenation (Adianergic Blumbourd			241
				242
	MADbreviations GMA MOITA			244
	Limitations General Peteronees		0.	244

164

ANTIHISTAMINE DRUGS —	
4:00 L.J. Wong	247
ANTI-INFECTIVE AGENTS —	O.
8:00 W.D. Ball	250
Antimicrobial Drugs of Choice, Chart	251
Agents Available from CDC, Chart	264
Anthelmintics — 8:08	266
Antibiotics — 8:12	
Aminoglycosides — 8:12.02, Vice Police (Control of the Control of	268
Antifungal Antibiotics — 8:12.04	276
Cephalosporins - 8:12.06 ARETAL QUAG	281
Chloramphenicol - 8:12.08 MA POLICE	289
Erythromycins — 8:12.12	290
The Penicillins — 8:12.16	294
The Tetracyclines — 8:12.24	308
Other Antibiotics - 8:12.28 OTATATAD	313
Antituberculosis Agents — 8:16 ANTIAUMMAI	318
Antivirals - 8:18 of the Antivirals - 8:18	325
Sulfonamides — 8:24	327
Urinary Germicides — 8:36	332
Other Anti-Infectives — 8:40 Mar JAOIO 3M	334
ANTINEOPLASTIC AGENTS —	
10:00 R.T. Dorr	344
Poisoning, W.G. Upulman	
AUTONOMIC DRUGS — 12:00 g3 au s18	
Parasympathomimetic (Cholinergic)	075
Agents — 12:04 W.G. Troutman	375
Parasympatholytic (Cholinergic Blocking)	ar
Agents — 12:08 S.K. Shimomura,	376
School Street Control Les Druces	57.8
Sympathomimetic (Adrenergic)  Agents — 12:12 L.R. Borgsdorf,	270
	379
L.J. Wong,	1. 2
Sympatholytic (Adrenergic Blocking)	
Agents — 12:16 tamo J.E. Knoben	393
BLOOD FORMATION AND COAGULATION	
20:00 analistimi	L

EXPECTORANTS AND COUGH

PREPARATIONS - 48:00 R.E. Pachorek

533

#### xiv CONTENTS

482

	GASTROINTESTINAL DRU	GS — 56:00	
	Antacids and Adsorbents -	Pardell non	
	56:04 ptroviuscoutnA b	W.G. Troutman,	535
	L.J. Davis	J.E. Knoben,	
		J.K. Siepler	
	Anti-Diarrhea Agents —	J.K. Siepler,	
	80:35 LAS DRUGS — 24:00		539
	San Land	P.O. Anderson	
42	Cathartics and Laxatives -	J.K. Siepler,	E 40
48	ents 24:06 R.C. Eschbach		540
D.D.	Emetics and Anti-Emetics		
	- 256:200 METRYS SUOV		544
28:90	Miscellaneous Gastrointes		044
	Drugs — 56:40	P.O. Anderson,	551
		J.K. Siepler	
74	HORMONES AND SYNTH		
747	SUBSTITUTES — 68:00	Antidonyulsani	
	Adrenals — 68:04 150 A 01111	R F Smith	556
	6.L. Stimmel	L.J. Wona	000
	Contraceptives — 68:12		563
	Estrogens — 68:16	B.J. Dong	570
489	Insulins and Anti-Diabetic	Tranquilizers	
	Agents - 68:20 99819810	R.R. Conte,	577
	G.L. Stimmel	P.O. Anderson	
	Progestogens — 68:32	B.J. Dong	589
495	Thyroid and Antithyroid —	28:24	
	RE68:36 DIA DIROJAD .	R.E. Smith	591
	SPASMOLYTIC AGENTS -	BALANGE -	
	86:00 — enclude	L.J. Wong	602
	VITAMINS — 88:00	P.O. Anderson	608
ата 17	UNCLASSIFIED THERAPE		
517	AGENTS - 92:00		
	Antigout Agents		611
	Antiparkinson Agents	S.K. Shimomura	613
	Bromocriptine	P.O. Anderson	617
	Cromolyn	L.J. Wong	618
INDEX			621

## 1

## ABBREVIATIONS AND CONVERSION FACTORS

THE FOLLOWING medical record and prescription abbreviations are in common usage, but variations will occur by institution or geographic area.

#### **Medical Record Abbreviations**

.A	Apical; Artery; Assessment (POMR)	ASHD	Arteriosclerotic heart disease
Az Soci	Aortic second sound	ASO	Arteriosclerosis obliterans
AAL	Anterior axillary line	ATN	Acute tubular necrosis
Ab	Abort; Abortion; Antibody	AV	Arteriovenous; Atrioventricular
Abd	Abdomen; Abdominal	A&W	Alive and well
ABE	Acute bacterial endocarditis	Ax	Axillary and is replaced part of the control of the
ABG	Arterial blood gases	BaE FIRM	
ACD	Acid citrate dextrose; Anterior chest	BBB	Bundle branch block
	diameter \$199 (ASDIVER)	BBT	Basal body temperature
ACT	Activated clotting time	BCG	Bacille Calmette-Guerin
ACTH	Adrenocorticotropic hormone	BE	Bacterial endocarditis; Barium enema
ADH -	Antidiuretic hormone	BEI	Butanol-extractable iodine
ADL	Activities of daily living	BJ	Biceps jerk; Bone and joint
ADR	Adverse drug reaction	BK	Below knee
AF	Atrial fibrillation	BI Obs	Bladder observation
AFB	Acid fast bacillus	BLS	Basic life support
Ag XX	Antigen of last listed block William	BM	Bone marrow: Bowel movement
A/G	Albumin/globulin ratio	BMR	Basal metabolic rate
AGL	Acute granulocytic leukemia	BP	Blood pressure XQO
AGN	Acute glomerular nephritis	BPH	Benign prostatic hypertrophy
AHF	Antihemophilic factor	BR S	Bathroom: Bedrest
AHG	Antihemophilic globulin	BRP	Bathroom privil as
Al Espe	Aortic insufficiency	BS	Blood sugar; Bowel sounds; Breath
AJ	Ankle jerk		Sounds ment spieded . MaC
AK	Above knee	BSA	Body surface area
ALL	Acute lymphocytic leukemia	BSO	Bilateral salpingo-oophorectomy
AMA	Against medical advice	BT	Bedtime; Brain tumor; Breast tumor
AML	Acute myelocytic leukemia	BTFS	Breast tumor frozen section
ANA	Antinuclear antibodies	BTL	Bilateral tubal ligation
AODM	Adult onset diabetes mellitus	BU	Bodansky unit
AP	Antepartum; Anteroposterior; Apical	BUN	Blood urea nitrogen
	pulse 6/63 (1684	BVL	Bilateral vas ligation
A&P	Anterior and posterior; Auscultation	BW	Body weight
	and percussion	Bx	Biopsy
Арру	Appendectomy	Cz	Second cervical vertebra
APTT	Activated partial thromboplastin time	CA	Cancer; Carcinoma; Chronologic age
ARD	Acute respiratory disease; Acute	CABG	Coronary artery bypass graft
	respiratory distress	CAD	Coronary artery disease
ARF	Acute renal f: lure	CAPD	Chronic ambulatory peritoneal dialysis
AS	Anal sphincter: Aortic stenosis;	CAT	Computerized axial tomography
10	Arteriosclerosis	CBC	Complete blood count
ASCVD	Arteriosclerotic cardiovascular disease	CBS	Chronic brain syndrome
ASD	Atrial septal defect	CC	Chit complaint

#### 2 CLINICAL DRUG DATA

CCU	Coronary care unit		EKG	Electrocardiogram	
CF	Complement fixation; Cystic fibro	sis	EMG	Electromyogram	
COH	Chorionic gonadotropic hormone		ENT	Ears, nose and throat	
CGL	Chronic granulocytic leukemia		ER	Emergency room	
CHD	Congenital heart disease; Corona	rv .	ESR	Erythrocyte sedimentation rate	
OHD	heart disease	,	EST	Electroshock therapy	
CHF	Congestive heart failure		EUA	Examine under anesthesia	
			FAS	Fetal alcohol syndrome	
СНО	Carbohydrate		FB	Finger breadths; Foreign bodies	
CI	Cardiac index; Color index		-		(Jes
CLL	Chronic lymphocytic leukemia	1100	FBS	Fasting blood sugar	
CML	Chronic myelocytic leukemia	:VN:	F Cath	Foley catheter	12
CNS	Central nervous system		FEV.	Forced expiratory volume in one	79
CO	Cardiac output	13 - 1A	0101	second	
CIO	Complaint of	1 2 2 3	FF	Filtration fraction	
COLD	Chronic obstructive lung disease		FFA	Free fatty acids	
COPD	Chronic obstructive pulmonary		FH	Family history; Fetal heart	
	disease		FHR	Fetal heart rate	
CAP	Cystoscopy and pyelogram	on house	FHS	Fetal heart sounds	LaT'
CPAP	Continuous positive airway press	ure	FP	Family planning	
CPK	Creatine phosphokinase		FRC	Functional residual capacity	
CPP .	Cerebral perfusion pressure		FSH	Follicle stimulating hormone	
CPR	Cardiopulmonary resuscitation		FTA	Fluorescent titer antibody; Fluore	
CRF	Chronic renal failure; Corticotrop	in	110	treponemal antibody	
Onr			FTND	Full-term normal delivery	
CRP	releasing factor C-reactive protein	fA b	FUO	Fever of undetermined origin	
CS	Cesarean section; Coronary scien	neie			
		USIS	FVC	Forced vital capacity	
Cas	Culture and sensitivity	BA"	FX	Fracture A Maria Maria	A
	C Culture, sensitivity and colony of	unt	GA	Gastric analysis; General appeara	INCO
CSF	Cerebrospinal fluid		GB .		高高
CT	Circulation time; Clotting time;		GC	Gonococcal; Gonococcus	SA
	Computerized tomography	5 AT .	GFR	Glomerular filtration rate	Albe
CUC	Chronic ulcerative colitis		GH	Growth hormone	GA
CV	Cardiovascular; Conjugata vera	205	GI		TA
CVA	Cerebral vascular accident; Cost	OVOI-	GMP		DA -
		150 -	G-P-	Gravida-, para-	
CVI	Cerebral vascular insufficiency		GSPD	Glucose-6-phosphate dehydroger	lase
CVP		38	GTT	Glucose tolerance test	40.00
CVS		38	GU		UA-
Cx	Cervical; Cervix	FB	Gyn		
CXR			HA		CA.
DC or	Control of the contro	N8	HAA	the state of the s	
D/C				11 4141 - 10 41	FA
			HBAg HB/BW		TA.
DAC		N.S		Hold breakfast for blood work	04
DD or	Differential diagnosis	868	HBP		
DDX	Significant property of	98	HCG		
DDD		1818	Hct		
DHL	Diffuse histiocytic lymphoma	88	HCVD	Hypertensive cardiovascular dise	lase
DIH	Differential blood count	28	HDL	High-density lipoproteins	416
DJD	Degenerative joint disease		HEENT	Head, eyes, ears, nose, throat	
DM	Diabetes mellitus; Diastolic mun	mur	Hgo	Hemoglobin	
DOA	Date of admission; Dead on arri		HHD	Hypertensive heart disease	
DOE			HNV		10
DPT	Diphtheria-pertussis-tetanus	76	HO	44-11-11-11-11-11-11-11-11-11-11-11-11-1	
DSD	Do: steelle descripe	1.60	H/O		
DTR	Doon tondon rollou		HPF	History of High power field	MA
DTs	Delirium tremens		HPI	History of present illness	
DU	Duodenal vicer	UB	HPLC		vanhu
		WA .		High pressure liquid chromatogr	apily
DW	Dextrose in water; Distilled water		HR	Heart rate	
D5W		ALE	HT	Hypertension, Hypodermic table	1 TA
Dx	Diagnosis		HTN	Hypertension	
EBL	Estimated blood loss		HTVD	Hypertensive vascular disease	
ECF	Extracellular fluid	A:0	HX	History	
ECG	Electrocardiogram		I stuck	Impression (POMR)	
ECT	Electroconvulsive therapy		IA	Intra-amniotically	
EDTA	Ethylenediaminetetraacetate		IASD	Interatrial septal defect	
EEG			IBC	Iron binding capacity	
EENT			IBI	Intermittent bladder irrigation	
EFA	Essential fatty acids		ICF	Intracellular fluid	
Dec 14	Federicial latty and				

ICG	Indocyanine green	LVH	Left ventricular hypertrophy
ICM	Interceptal margin	L&W	Living and well
ICS	Intercostal space	Lytes	Flectrolytes
ICSH	Interstitial cell-stimulating hormone	M	Motor: Molar: Murmur
ICU	Intensive care unit	M.	Added fleet cound
		MA	
ID	Initial dose; Intradermal(ly)		Mental age
I & D	Incision and drainage	M/A	Mood and/or affect
IF alliana	Inspiratory force; Interstitial fluid; In-	MAP	Mean arterial pressure
	trinsic factor	MBC	Maximum breathing capacity;
lg	Immunoglobulin		Minimum bactericidal concentration
IHD	Ischemic heart disease	MCH	Mean corpuscular hemoglobin
ILDL	Intermediate low-density lipoproteins	MCHC	Mean corpuscular hemoglobin concen-
IM	Intramuscular(ly)		tration
IMP.	Impression	MCL	Midclavicular line; Midcostal line
IMV	Intermittent mechanical ventilation	MCV	Mean cornuscular volume
180	totales and auto a	MDV	Multiple dose vial
IOP	Intraocular pressure	MF	Myocardial fibrosis
IP	Intraperitoneal(ly)	MH	Marital history; Menstrual history
IPPB	Intermittent positive pressure	MI	Mitral insufficiency; Myocardial infarc-
ILLO.	breathing	20	tion
17		100	LT PROPERTY FOR THE THE WINDOWS AND AND AND ADDRESS OF THE PROPERTY ADDRESS OF THE PRO
IT	Inhalation therapy; Intrathecal(ly)	MIC	Minimum inhibitory concentration
IU	International unit	ML	Midline
IUCD or	Intrauterine (contraceptive) device	MLD	Minimum lethal dose
IUD	SOB Stodness of breath	MS	Mitral stenosis; Morphine sulfate;
IUP	Intrauterine pregnancy		Multiple sclerosis
IV	Intravenous(ly)	MSL	Ministernal line
IVP	Intravenous push; Intravenous	N or-NL	Normal
Waran Stra	pyelogram	NAD	No acute distress
IVPB	Intravenous piggyback	NAS	NO added sait
IVSD	Interventricular septal defect	NG	Nasogastric hagits9
JVD	Jugular-venous distention	NGU	Nongonococcal urethritis
JVP	Jugular-venous nulse	NKA :	No known allergies
KJ	Knee lerk	NPN	Nonprotein nitrogen
KO	Keep open	NPO	Mathing by mouth
KUB	Kidneys, ureters, bladder	NS	Normal saline
KVO	Keep vein open	NSFTD	Normal spontaneous full-term delivery
KW	Keith-Wagener (ophthalmoscopic find-	NSR	Normal sinus rhythm
Villo.	ings)	NSU	Nonspecific urethritis
L	Left a Highendmont OAT	N & T	Nose and throat
	Second lumbar vertebra		
Lz .		N & V	Nausea and vomiting
LA	Left atrium	NVD	Mausea, voilitting, diarrilea
Lap	Laparotomy	NYD	Not yet diagnosed
LATS	Long-acting thyroid stimulator	0	Objective data (PUMK)
LBBB	Left bundle branch block	Ob	Obstetrics
LCM	Lett costal margin	OB	Obstetrics Occult blood
LD	Lethal dose; Liver disease; Longi-	OBS	Organic brain syndrome
	tudinal diameter (of heart)	O/E	On examination
LDH	Lactic dehydrogenase	OOB	Out of bed
LDL	Low-density lipoproteins	OPV	Outpatient visit; Oral pollo vaccine
LE	Lower autremities: Lunus	OR	Operating room
	andhamataque	OT	Occupational therapy; Old tuberculin
LFS	Liver function series	P	Dian (DOMD): Dules
LFT	Liver function test(s)	PA	Pernicious anemia; Posteroanterior;
LH	Luteinizing hormone		Pulmonary artery
LKS	Liver kidneye enleen	P & A	Percussion and auscultation
LLD	Left leteral depublica	PABA	Para-aminobenzoic acid
		PADA	
LLL	Left lower lobe		Paroxysmai atriai tacifycardia
LLQ	Left lower quadrant	PBI	Protein bound louine
LMP	Last menstrual period	PC	Porto-cavai, Present complaint
LOA	Left occipital anterior	PCS	Porto-cavar shunt
LOM	Limitation of motion	PCV	Packed cell volulle
LOP	Lett occipital posterior	PE	Physical examination; Pulmonary em-
LP	Light perception; Lumbar puncture		bolism
LPF	Low power field	PEEP	Positive end-expiratory pressure
LT	Levine tube; Luken's trap	PEG	Pneumoencephalogram; Polyethylene
LTC	Long term care		glycol
LUL	Left upper lobe	PERLA	Pupils equal, react to light and ac-
LUQ	Left upper quadrant		commodation .

#### 4 CLINICAL DRUG DATA

PFT	Pulmonary function test(s)	RTC	Return to clinic
PGH	Pituitary growth hormone	RUL	Right upper lobe
pHa	Arterial blood pH	RUQ	Right upper quadrant
PH		RVH	Right ventricular hypertrophy
	Patient history	W. 2004 No. 114 April 1	
PI	Present illness	S	Subjective data (POMR)
PID	Pelvic inflammatory disease	S <sub>1</sub>	First heart sound
PIE	Pulmonary infiltration with eosinophilia	S <sub>2</sub>	Second heart sound
PKU	Phenylketonuria	S-A	Sino-atrial
-PMH	Past medical history	SBE	Subacute bacterial endocarditis
PMI	Point of maximal impulse; Point of	SBO	Small bowel obstruction
TOTAL HE	maximal intensity	SC	Sickle cell: Static compliance: Subcla-
PMN	Polymorphonuclear leukocytes	-	vian; Subcutaneous(ly)
PMP		SGOT	
	Past menstrual period	3001	Serum glutamic oxaloacetic transami-
PM &			nase
PMT	Premenstrual tension	SGPT	Serum glutamic pyruvic transaminase
PND	Paroxysmal nocturnal dyspnea; Post-	SH	Serum hepatitis; Social history
	nasal drip	SIADH	Syndrome of inappropriate ADH
Pnx			(secretion)
PO		SL	Sublingual(ly)
POLY		SLE 811	Systemic lupus erythematosus
	Droblem oriented medical record	SMA	
POME			Serial multiple analysis
POR	Problem oriented record	SMR	Somnolent metabolic rate
PP	Postpartum; Postprandiai	SOAP	Subjective, objective, assessment and
PPBS	Postprandial blood sugar		plans (POMR)
PPD	Purified protein derivative	SOB	Shortness of breath
ppm	Parts per million	S/P	Status post
PR	Per rectum	SQ	Subcutaneous(ly)
PAR	Pulse and reeniration	SR	Sedimentation rate; Systems review
PSP	Dhanalau Manahthalain	SSE	
		33E	Saline solution enema; Soap solution
Pt	Patient and an arms and a series	150	enema (Latin
PT	Physical therapy; Prothrombin time	STD	Sexually transmitted disease; Skin test
PTA	Plasma thromboplastic antecedent;		dose
	Prior to admission; Prothrombin	STS	Serologic test for syphilis
	activity	Sx	Symptom(s)
PTC	Plasma thromboplastin component	T	Temperature
PTT	Partial thromboplastin time	T&A	Tonsillectomy and adenoidectomy
PU	Peptic ulcer	TAb	Therapeutic abortion
PUD	Peptic ulcer disease	TAH	Total abdominal hysterectomy
PVC	Premature ventricular contraction	TAO	Thromboangiitis obliferans
PVT	Paroxysmal ventricular tachycardia	TAT	Tetanus antitoxin
Px	Physical examination; Pneumothorax	TB	Tuberculosis
R	Respiration; Right	TBA	To be administered; To be arranged
RA	Rheumatoid arthritis: Right atrium	TBG	Thyroxine binding globulin
RAL	Radioactive iodine	TBW	Total body water
RBBE		T&C	
			Type and crossmatch
RBC	Red blood cell; Red blood count	TD	Transverse diameter (of heart)
RBF	Renal blood flow	TEA	Thromboendartectomy
RCM	Right costal margin	TIA	Transient ischemic attack
RDS	Respiratory distress syndrome	TIBC	Total iron-binding capacity
REM	Rapid eve movement	TKO	To keep open
RF	Renal failure; Rheumatic fever; Rheu-	TL	Tubal ligation
MEGD31	matoid factor	TLA	Trans-lumbar aortogram
Ph.	- 1		
Rh	Rhesus factor	TLC	Tender loving care; Thin layer chro-
RHD	Rheumatic heart disease		matography
RIA	Radioimmunoassay	Tm	Maximal renal tubular clearance
ALD	Right lateral decubitus	TM	Tympanic membrane
RLL	Right lower lobe	TOPV	Trivalent oral polio vaccine
RLQ	Right lower quadrant	TP	Thrombophlebitis; Total protein
R/O	Rule out	TPI	Treponema pallidium immobilization
ROM		TPN	
			Total parenteral nutrition
ROS	Review of symptoms; Review of sys-	TPR	Temperature, pulse, respiration
-280 VI	tems reminisce tableville - 9.9	T-set	Tracheotomy set
ROT	Right occipital transverse	TSH	Thyroid stimulating hormone
RPF	Renal plasma flow	TURP	Transurethral resection of prostate
RQ	Respiratory quotient	TV	Trichomonas vaginalis
RR	Recovery room; Respiratory rate	TVC	Triple voiding cystogram
RSR	Regular sinus rhythm	TWE	Tap water enema
RTA	Renal tubular acidosis	Tx	Treatment